Numinus Wellness Names Kelvin Yang as CFO-February 2024-www.financetom.com

Numinus Wellness Names Kelvin Yang as CFO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Numinus Wellness Names Kelvin Yang as CFO

Feb 19, 2025 3:51 AM

06:44 AM EST, 02/19/2025 (MT Newswires) -- Numinus Wellness ( NUMIF ) overnight Tuesday named Kelvin Yang as interim chief financial officer.

Yang is replacing Melony Valleau, who will conclude her interim tenure at the end of February.

Previous page： Diamondback Energy misses estimates for third-quarter profit Next page： Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Diamondback Energy misses estimates for third-quarter profit

Nov 4, 2024

Nov 4 (Reuters) - Diamondback Energy ( FANG ) missed estimates for third-quarter profit on Monday as the oil and gas firm was hurt by lower prices. The company reported an adjusted profit of $3.38 per share for the quarter ended Sept. 30, compared with analysts' average estimate of $3.98 per share, according to data compiled by LSEG. (Reporting by...

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Nov 4, 2024

(Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion, according to...

--Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion

Nov 4, 2024

04:03 PM EST, 11/04/2024 (MT Newswires) -- Price: 468.00, Change: -3.12, Percent Change: -0.66 ...

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Nov 4, 2024

Nov 4 (Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion,...